Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article - Biomedical Research (2017) Volume 28, Issue 13

Effect of rosiglitazone on the expression of tumor necrosis factor-α in the liver tissue of mice with non-alcoholic steatohepatitis

The aim of this study was to investigate the effect of rosiglitazone on the expression of Tumor Necrosis Factor-α (TNF-α) in the liver tissue of mice with Non-Alcoholic Steatohepatitis (NASH) and its role in NASH progression. Fifteen healthy male C57BL/6J mice were randomly divided into three groups: the control group (MCD+), the model group (MCD-), and the rosiglitazone group (MCD ± R). The serum alanine aminotransferase (ALT) and triglyceride (TG) levels were detected using the enzyme method. Hematoxylin-Eosin (HE) staining was performed to observe steatosis, inflammation, and fibrosis in the liver tissue. Reverse Transcription Polymerase Chain Reaction (RT-PCR) and western blotting were performed to detect the expression of TNF-α mRNA and protein. Liver pathology: the MCD+ group showed no significant liver steatosis, inflammation, and fibrosis; the MCD- group showed obvious steatosis and inflammation. However, the MCD ± R group exhibited reduced lesions. The expression of TNF-α mRNA and protein in the liver tissue among the groups was as follows: group MCD ≥ group MCD ± R>group MCD+. In the mouse models of NASH, the TNF-α expression in the liver tissue was related to the progression of NASH; Rosiglitazone can inhibit the expression of TNF-α and prevent the progression of NASH, thus providing new ideas for selecting therapeutic targets for NASH.

Author(s): Lei Wang, Yuemin Nan, Xiaodong Yuan

Abstract Full Text PDF